IBD LIVE Case Series: Case 9: Do Race and Extraintestinal Manifestations Affect Treatment of Severe Crohn's Colitis?

Siobhan S. Proksell; Julia B. Greer; Brian K. Theisen; Peter L. Davis; Joel R. Rosh; David J. Keljo; Alka Goyal; Samir A. Shah; Myron H. Brand; Hans H. Herfarth; Raymond K. Cross; Corey A. Siegel; Walter A. Koltun; Kim L. Isaacs; Miguel D. Regueiro

doi:10.1093/ibd/izx114

IBD LIVE Case Series: Case 9: Do Race and Extraintestinal Manifestations Affect Treatment of Severe Crohn's Colitis?

Siobhan S. Proksell, Julia B. Greer, Brian K. Theisen, Peter L. Davis, Joel R. Rosh, David J. Keljo, Alka Goyal, Samir A. Shah, Myron H. Brand, Hans H. Herfarth, Raymond K. Cross, Corey A. Siegel, Walter A. Koltun, Kim L. Isaacs, Miguel D. Regueiro

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	698-713
Number of pages	16
Journal	Inflammatory bowel diseases
Volume	24
Issue number	4
DOIs	https://doi.org/10.1093/ibd/izx114
State	Published - Mar 19 2018

All Science Journal Classification (ASJC) codes

Immunology and Allergy
Gastroenterology

Access to Document

10.1093/ibd/izx114

Cite this

Proksell, S. S., Greer, J. B., Theisen, B. K., Davis, P. L., Rosh, J. R., Keljo, D. J., Goyal, A., Shah, S. A., Brand, M. H., Herfarth, H. H., Cross, R. K., Siegel, C. A., Koltun, W. A., Isaacs, K. L., & Regueiro, M. D. (2018). IBD LIVE Case Series: Case 9: Do Race and Extraintestinal Manifestations Affect Treatment of Severe Crohn's Colitis? Inflammatory bowel diseases, 24(4), 698-713. https://doi.org/10.1093/ibd/izx114

@article{a11af3baa7a54b32bcf83e4a9023b9ea,

title = "IBD LIVE Case Series: Case 9: Do Race and Extraintestinal Manifestations Affect Treatment of Severe Crohn's Colitis?",

author = "Proksell, {Siobhan S.} and Greer, {Julia B.} and Theisen, {Brian K.} and Davis, {Peter L.} and Rosh, {Joel R.} and Keljo, {David J.} and Alka Goyal and Shah, {Samir A.} and Brand, {Myron H.} and Herfarth, {Hans H.} and Cross, {Raymond K.} and Siegel, {Corey A.} and Koltun, {Walter A.} and Isaacs, {Kim L.} and Regueiro, {Miguel D.}",

note = "Funding Information: Conflicts of Interest: Julia B. Greer holds a grant from AbbVie. Joel R. Rosh serves as a consultant to and has received grant support from AbbVie and Janssen. Samir A. Shah is on the Speaker{\textquoteright}s Bureau for AbbVie, Janssen, and Takeda. Myron H. Brand serves on the Speakers Bureaus of Abbvie, Gilead, Takeda, and Intercept Pharmaceuticals. Hans H. Herfarth receives consulting fees from Pfizer, Celltrion, Samsung, Merck, and UCB. RaymondK. Cross has participated in Advisory Boards and/or consulting for Janssen, Abbvie, UCB, and Takeda. Corey A. Siegel serves as a consultant to AbbVie, Amgen, Lilly, Janssen, Sandoz, Pfizer, Prometheus, Takeda, and UCB, delivered CME activities to American Regent, AbbVie, Janssen, Pfizer, andTakeda, received grant support from AbbVie, Janssen, Pfizer, and Takeda. Kim. L. Isaacs consults on the Data Safety Monitoring Board for Medimmune and Janssen. Miguel D. Regueiro serves on the Advisory Boards and consults for AbbVie, Janssen, Pfizer, Takeda, and UCB. All authors and staff in a position to control the content of this CME activity and their spouses/life partners (if any) have disclosed that they have no financial relationships with, or financial interests in, any commercial organizations pertaining to this educational activity. Funding Information: Financial Support: Supported by a portion of funding for this work was provided by the Sigal Family Research & Education Inflammatory Bowel Disease Fund. Funding for the audiovisual conferences, but not for the article, was provided by unrestricted educational grants from AbbVie Inc., Shire US Inc., Takeda Pharmaceuticals Inc., and Pfizer Inc.",

year = "2018",

month = mar,

day = "19",

doi = "10.1093/ibd/izx114",

language = "English (US)",

volume = "24",

pages = "698--713",

journal = "Inflammatory bowel diseases",

issn = "1078-0998",

publisher = "Oxford University Press",

number = "4",

}

Proksell, SS, Greer, JB, Theisen, BK, Davis, PL, Rosh, JR, Keljo, DJ, Goyal, A, Shah, SA, Brand, MH, Herfarth, HH, Cross, RK, Siegel, CA, Koltun, WA, Isaacs, KL & Regueiro, MD 2018, 'IBD LIVE Case Series: Case 9: Do Race and Extraintestinal Manifestations Affect Treatment of Severe Crohn's Colitis?', Inflammatory bowel diseases, vol. 24, no. 4, pp. 698-713. https://doi.org/10.1093/ibd/izx114

TY - JOUR

T1 - IBD LIVE Case Series

T2 - Case 9: Do Race and Extraintestinal Manifestations Affect Treatment of Severe Crohn's Colitis?

AU - Proksell, Siobhan S.

AU - Greer, Julia B.

AU - Theisen, Brian K.

AU - Davis, Peter L.

AU - Rosh, Joel R.

AU - Keljo, David J.

AU - Goyal, Alka

AU - Shah, Samir A.

AU - Brand, Myron H.

AU - Herfarth, Hans H.

AU - Cross, Raymond K.

AU - Siegel, Corey A.

AU - Koltun, Walter A.

AU - Isaacs, Kim L.

AU - Regueiro, Miguel D.

N1 - Funding Information: Conflicts of Interest: Julia B. Greer holds a grant from AbbVie. Joel R. Rosh serves as a consultant to and has received grant support from AbbVie and Janssen. Samir A. Shah is on the Speaker’s Bureau for AbbVie, Janssen, and Takeda. Myron H. Brand serves on the Speakers Bureaus of Abbvie, Gilead, Takeda, and Intercept Pharmaceuticals. Hans H. Herfarth receives consulting fees from Pfizer, Celltrion, Samsung, Merck, and UCB. RaymondK. Cross has participated in Advisory Boards and/or consulting for Janssen, Abbvie, UCB, and Takeda. Corey A. Siegel serves as a consultant to AbbVie, Amgen, Lilly, Janssen, Sandoz, Pfizer, Prometheus, Takeda, and UCB, delivered CME activities to American Regent, AbbVie, Janssen, Pfizer, andTakeda, received grant support from AbbVie, Janssen, Pfizer, and Takeda. Kim. L. Isaacs consults on the Data Safety Monitoring Board for Medimmune and Janssen. Miguel D. Regueiro serves on the Advisory Boards and consults for AbbVie, Janssen, Pfizer, Takeda, and UCB. All authors and staff in a position to control the content of this CME activity and their spouses/life partners (if any) have disclosed that they have no financial relationships with, or financial interests in, any commercial organizations pertaining to this educational activity. Funding Information: Financial Support: Supported by a portion of funding for this work was provided by the Sigal Family Research & Education Inflammatory Bowel Disease Fund. Funding for the audiovisual conferences, but not for the article, was provided by unrestricted educational grants from AbbVie Inc., Shire US Inc., Takeda Pharmaceuticals Inc., and Pfizer Inc.

PY - 2018/3/19

Y1 - 2018/3/19

UR - http://www.scopus.com/inward/record.url?scp=85044467705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044467705&partnerID=8YFLogxK

U2 - 10.1093/ibd/izx114

DO - 10.1093/ibd/izx114

M3 - Article

C2 - 29562279

AN - SCOPUS:85044467705

SN - 1078-0998

VL - 24

SP - 698

EP - 713

JO - Inflammatory bowel diseases

JF - Inflammatory bowel diseases

IS - 4

ER -

IBD LIVE Case Series: Case 9: Do Race and Extraintestinal Manifestations Affect Treatment of Severe Crohn's Colitis?

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Cite this